Broderick Brian C Sells 330 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Broderick Brian C cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,671 shares of the pharmaceutical company’s stock after selling 330 shares during the period. Vertex Pharmaceuticals comprises about 1.6% of Broderick Brian C’s investment portfolio, making the stock its 25th largest position. Broderick Brian C’s holdings in Vertex Pharmaceuticals were worth $7,867,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Kidder Stephen W lifted its holdings in shares of Vertex Pharmaceuticals by 1.4% during the second quarter. Kidder Stephen W now owns 12,130 shares of the pharmaceutical company’s stock valued at $5,400,000 after acquiring an additional 164 shares during the period. Somerville Kurt F raised its position in Vertex Pharmaceuticals by 1.4% in the 2nd quarter. Somerville Kurt F now owns 23,186 shares of the pharmaceutical company’s stock worth $10,322,000 after purchasing an additional 310 shares during the last quarter. REAP Financial Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 128.3% during the second quarter. REAP Financial Group LLC now owns 137 shares of the pharmaceutical company’s stock valued at $61,000 after acquiring an additional 77 shares during the period. Shell Asset Management Co. boosted its stake in shares of Vertex Pharmaceuticals by 28.5% in the 2nd quarter. Shell Asset Management Co. now owns 17,181 shares of the pharmaceutical company’s stock valued at $7,649,000 after purchasing an additional 3,809 shares during the last quarter. Finally, KLP Kapitalforvaltning AS boosted its stake in Vertex Pharmaceuticals by 5.8% in the second quarter. KLP Kapitalforvaltning AS now owns 92,841 shares of the pharmaceutical company’s stock valued at $41,333,000 after acquiring an additional 5,100 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $410.28 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The company has a fifty day moving average of $396.79 and a 200-day moving average of $441.11. The company has a market capitalization of $105.19 billion, a PE ratio of 29.33 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the previous year, the business earned ($12.83) earnings per share. Vertex Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director owned 45,000 shares in the company, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on VRTX shares. Scotiabank lowered their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. Cantor Fitzgerald reduced their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Stifel Nicolaus dropped their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. Finally, BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $493.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.